Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.48 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | MOGAT2 | Q3SYC2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13133948 | 0.94 | HTR5A (0.50) | HRH3PNMTHTR5ADRD2DRD3 | |
| SCHEMBL14046241 | 0.88 | POLB (0.41) | HRH3HTR5ADRD2DRD3MOGAT2 | |
| SCHEMBL16624019 | 0.86 | ACACB (0.52) | HRH3PNMTDRD2DRD3DRD1 | |
| SCHEMBL27271347 | 0.81 | DRD2 (0.50) | HRH3PNMTHTR5ADRD2DRD3 | |
| SCHEMBL24478252 | 0.81 | HRH3 (0.46) | HRH3PNMTHTR5ADRD2DRD3 | |
| SCHEMBL24478248 | 0.81 | MOGAT2 (0.43) | HRH3HTR5ADRD2DRD3MOGAT2 | |
| SCHEMBL12928759 | 0.81 | ABCB1 (0.43) | HRH3HTR5ADRD2DRD3MOGAT2 | |
| SCHEMBL19798869 | 0.81 | TMEM97 (0.56) | HRH3PNMTDRD3POLBACACB | |
| SCHEMBL6369620 | 0.79 | HRH3 (0.47) | HRH3PNMTHTR5ADRD2DRD3 | |
| SCHEMBL24478557 | 0.79 | HRH3 (0.44) | HRH3PNMTHTR5ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023078451-A1 | COMPOUND USED AS CDK7 KINASE INHIBITOR AND USE THEREOF | 浙江同源康医药股份有限公司 | 2023-05-11 | — | — | WO | disclosed |
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | HRH3 4083/4885PNMT 4376/4885HTR5A 4426/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | HRH3 3674/4885PNMT 3896/4885HTR5A 4333/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | HRH3 4216/4885PNMT 4410/4885HTR5A 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.